[go: up one dir, main page]

AU1099000A - Novel compounds and compositions for treating hepatitis c infections - Google Patents

Novel compounds and compositions for treating hepatitis c infections

Info

Publication number
AU1099000A
AU1099000A AU10990/00A AU1099000A AU1099000A AU 1099000 A AU1099000 A AU 1099000A AU 10990/00 A AU10990/00 A AU 10990/00A AU 1099000 A AU1099000 A AU 1099000A AU 1099000 A AU1099000 A AU 1099000A
Authority
AU
Australia
Prior art keywords
infections
compositions
novel compounds
treating hepatitis
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU10990/00A
Inventor
Jason M. Hataye
Kenneth Rice
Emma J. Shelton
Jeffrey R. Spencer
Vivian R. Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axys Pharmaceuticals Inc
Original Assignee
Axys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axys Pharmaceuticals Inc filed Critical Axys Pharmaceuticals Inc
Publication of AU1099000A publication Critical patent/AU1099000A/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • C07F9/65068Five-membered rings having the nitrogen atoms in positions 1 and 3 condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU10990/00A 1998-10-05 1999-10-04 Novel compounds and compositions for treating hepatitis c infections Abandoned AU1099000A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10308598P 1998-10-05 1998-10-05
US60103085 1998-10-05
PCT/US1999/022850 WO2000020400A1 (en) 1998-10-05 1999-10-04 Novel compounds and compositions for treating hepatitis c infections

Publications (1)

Publication Number Publication Date
AU1099000A true AU1099000A (en) 2000-04-26

Family

ID=22293315

Family Applications (1)

Application Number Title Priority Date Filing Date
AU10990/00A Abandoned AU1099000A (en) 1998-10-05 1999-10-04 Novel compounds and compositions for treating hepatitis c infections

Country Status (2)

Country Link
AU (1) AU1099000A (en)
WO (1) WO2000020400A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1313734B1 (en) 2000-09-01 2009-11-11 Novartis Vaccines and Diagnostics, Inc. Aza heterocyclic derivatives and their therapeutic use
EP1650203B1 (en) * 2000-09-11 2008-02-20 Novartis Vaccines and Diagnostics, Inc. Process of preparation of benzimidazol-2-yl quinolinone derivatives
AU2002230763A1 (en) * 2000-12-13 2008-01-03 Bristol-Myers Squibb Pharma Company Inhibitors of hepatitis c virus ns3 protease
US6653295B2 (en) 2000-12-13 2003-11-25 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus NS3 protease
US7026111B2 (en) * 2001-10-15 2006-04-11 Beckman Coulter, Inc. Methods and reagents for improved cell-based assays
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
US6642204B2 (en) 2002-02-01 2003-11-04 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
AU2003288899B2 (en) 2002-08-23 2009-09-03 Novartis Vaccines And Diagnostics, Inc. Benzimidazole quinolinones and uses thereof
US20050075279A1 (en) 2002-10-25 2005-04-07 Boehringer Ingelheim International Gmbh Macrocyclic peptides active against the hepatitis C virus
AU2003290699B2 (en) 2002-11-13 2009-08-27 Novartis Vaccines And Diagnostics, Inc. Methods of treating cancer and related methods
FI118418B (en) 2003-04-17 2007-11-15 Ecocat Oy Aluminum-rounded catalytic converter for cleaning of gas leaks
DK1654261T3 (en) 2003-05-21 2008-01-14 Boehringer Ingelheim Int Hepatitis C inhibitor compounds
ATE500264T1 (en) 2003-09-22 2011-03-15 Boehringer Ingelheim Int MACROCYCLIC PEPTIDES ACTIVE AGAINST HEPATITIS C VIRUS
DE602005025855D1 (en) 2004-01-21 2011-02-24 Boehringer Ingelheim Pharma MACROCYCLIC PEPTIDES WITH EFFECT TO THE HEPATITIS C VIRUS
US20070049593A1 (en) 2004-02-24 2007-03-01 Japan Tobacco Inc. Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor
DK1719773T3 (en) 2004-02-24 2009-06-29 Japan Tobacco Inc Condensed heterotetracyclic compounds and their use as HCV polymerase inhibitor
EP1771454B1 (en) 2004-07-20 2011-06-15 Boehringer Ingelheim International GmbH Hepatitis c inhibitor peptide analogs
UY29016A1 (en) 2004-07-20 2006-02-24 Boehringer Ingelheim Int ANALOGS OF INHIBITING DIPEPTIDES OF HEPATITIS C
NZ553408A (en) 2004-07-27 2010-10-29 Gilead Sciences Inc Imidazo[4,5-d]pyrimidines, their uses and methods of preparation
US7659263B2 (en) 2004-11-12 2010-02-09 Japan Tobacco Inc. Thienopyrrole compound and use thereof as HCV polymerase inhibitor
EP2465857B1 (en) 2005-05-17 2014-06-04 Novartis AG Methods for synthesizing heterocyclic compounds
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
EP1886685A1 (en) 2006-08-11 2008-02-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods, uses and compositions for modulating replication of hcv through the farnesoid x receptor (fxr) activation or inhibition
US7906655B2 (en) * 2008-08-07 2011-03-15 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2430015B1 (en) 2009-05-12 2015-06-17 Merck Sharp & Dohme Corp. Fused tricyclic compounds useful for the treatment of viral diseases
JP2012528195A (en) 2009-05-29 2012-11-12 メルク・シャープ・アンド・ドーム・コーポレーション Antibacterial compounds composed of three linked aryl moieties for treating diseases such as hepatitis C
WO2010138790A1 (en) 2009-05-29 2010-12-02 Schering Corporation Antiviral compounds composed of three aligned aryl moieties to treat diseases such as hepatitis c
US20120276047A1 (en) * 2009-11-25 2012-11-01 Rosenblum Stuart B Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases
JP2013515068A (en) 2009-12-22 2013-05-02 メルク・シャープ・アンド・ドーム・コーポレーション Fused tricyclic compounds for the treatment of viral diseases and methods of use thereof
CA2792121A1 (en) 2010-03-09 2011-09-15 Merck Sharp & Dohme Corp. Fused tricyclic silyl compounds and methods of use thereof for the treatment of viral diseases
TWI501967B (en) 2010-12-16 2015-10-01 Janssen R&D Ireland Azaindoles as respiratory syncytial virus antiviral agents
TWI515187B (en) 2010-12-16 2016-01-01 健生科學愛爾蘭無限公司 Anthraquinone as an antiviral agent for respiratory fusion virus
TWI527814B (en) 2010-12-16 2016-04-01 健生科學愛爾蘭無限公司 Azabenzimidazoles as respiratory syncytial virus antiviral agents
TWI530495B (en) 2010-12-16 2016-04-21 健生科學愛爾蘭無限公司 Benzimidazole respiratory syncytial virus inhibitors
TWI541241B (en) 2010-12-16 2016-07-11 健生科學愛爾蘭無限公司 Imidazopyridines as respiratory syncytial virus antiviral agents
WO2012107589A1 (en) 2011-02-11 2012-08-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
DE102011111991A1 (en) 2011-08-30 2013-02-28 Lead Discovery Center Gmbh New cyclosporin derivatives
TWI643850B (en) 2012-06-15 2018-12-11 健生科學愛爾蘭無限公司 Novel 1,3-dihydro-2h-benzimidazol-2-one derivatives substituted with heterocycles as respiratory syncytial virus antiviral agents
EP4165034A1 (en) 2020-06-11 2023-04-19 Janssen Sciences Ireland Unlimited Company Hemi (l)-tartrate forms of 3-({5-chloro-1-[3-(methylsulfonyl)propyl]-1h-indol-2 yl} methyl)-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2h-imidazo[4,5-c]pyridin-2-one and pharmaceutical compositions comprising the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH406305A (en) * 1960-09-30 1966-01-31 Gretag Ag Method and device for the simultaneous triggering of a switching process in at least two devices
US5693515A (en) * 1995-04-28 1997-12-02 Arris Pharmaceutical Corporation Metal complexed serine protease inhibitors
EE04055B1 (en) * 1997-04-07 2003-06-16 Axys Pharmaceuticals, Inc. Compounds and compositions for the treatment of diseases associated with serine protease activity, in particular tryptase activity, and their use

Also Published As

Publication number Publication date
WO2000020400A1 (en) 2000-04-13

Similar Documents

Publication Publication Date Title
AU1099000A (en) Novel compounds and compositions for treating hepatitis c infections
AU4813197A (en) Compositions and methods for treating viral infections
EP1128832A4 (en) Compounds, compositions and methods for treating or preventing viral infections and associated diseases
EP1292603B8 (en) Methods and compositions for treating hepatitis c virus
AU2951299A (en) Disinfecting compositions and processes for disinfecting surfaces
AU5898599A (en) Methods and compositions for genomic modification
AU1694497A (en) Disinfecting compositions and processes for disinfecting surfaces
AU2557800A (en) Preservative compounds and compositions
HUP0203746A3 (en) Novel composition and method for stabilizing the same
AU4392199A (en) Medicinal compositions for treating evacuatory insufficiency
AU2632899A (en) Condensed heterocyclic compounds as anti-inflammatory and immunomodulatory agents
AU3835399A (en) Perfume composition
AU5029700A (en) Glycopeptide antibacterial compounds, compositions containing same and methods of using same
AU7165498A (en) Methods for treating viral infections
AU3858600A (en) Glucamine compounds for treating hepatitis virus infections
AU1733300A (en) Copolymer compositions for treating viral infections
AU7961498A (en) 9a-azalides, compositions containing such compounds and methods of treatment
AU2021601A (en) Composition for the treatment of dandruff
AU7986098A (en) 9a-aza-3-ketolides, compositions containing such compounds and methods of treatment
GB9816252D0 (en) Molluscicidal composition
AU5704800A (en) Medicinal compositions for preventing or treating diarrhea
AU2207001A (en) Novel compounds and process
AU5056199A (en) Molluscicidal composition
AU2350195A (en) Surfactant composition
AU2961699A (en) Medicinal compositions for treating edema

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase